Back to Search
Start Over
STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.
- Source :
-
Urologic Oncology . Jul2021, Vol. 39 Issue 7, p438.e1-438.e9. 1p. - Publication Year :
- 2021
-
Abstract
- <bold>Objective: </bold>Improvements to bladder cancer risk stratification guidelines are needed to better tailor post-operative surveillance and adjuvant therapy to individual patients. We previously identified STAG2 as a commonly mutated tumor suppressor gene in bladder cancer and an independent predictor of progression in NMIBC. Here we test the value of combining STAG2 immunostaining with other risk stratification biomarkers in NMIBC, and as an individual biomarker in MIBC.<bold>Materials and Methods: </bold>STAG2 immunohistochemistry was performed on a progressor-enriched cohort of tumors from 297 patients with NMIBC, and on tumors from 406 patients with MIBC from Aarhus University Hospital in Denmark. Survival analysis was performed using Kaplan-Meier survival analysis, the log rank test, and Cox proportional hazards models.<bold>Results: </bold>STAG2-negative low-grade NMIBC tumors were 2.5 times less likely to progress to muscle invasion than STAG2-positive low-grade NMIBC tumors (Log-rank test, P = 0.008). In a composite group of patients with AUA intermediate and high-risk NMIBC tumors, STAG2-negative tumors were less likely to progress (Log-rank test, P = 0.02). In contrast to NMIBC, we show that STAG2 is not useful as a prognostic biomarker in MIBC.<bold>Conclusions: </bold>STAG2 immunostaining can be used to subdivide low-grade NMIBC tumors into two groups with substantially different risks of disease progression. Furthermore, STAG2 immunostaining may be useful to enhance NMIBC risk stratification guidelines, though larger cohorts are needed to solidify this conclusion in individual risk groups. STAG2 is not useful as a biomarker in MIBC. Further study of the use of STAG2 immunostaining as a biomarker for predicting the clinical behavior in NMIBC is warranted. [ABSTRACT FROM AUTHOR]
- Subjects :
- *BLADDER cancer
*BIOMARKERS
*CANCER invasiveness
*PROPORTIONAL hazards models
*TUMOR suppressor genes
*DISEASE risk factors
*UROTHELIUM
*RESEARCH
*RESEARCH methodology
*CELL cycle proteins
*PROGNOSIS
*RETROSPECTIVE studies
*MEDICAL cooperation
*EVALUATION research
*RISK assessment
*COMPARATIVE studies
*SURVIVAL analysis (Biometry)
*RESEARCH funding
*TUMOR grading
BLADDER tumors
Subjects
Details
- Language :
- English
- ISSN :
- 10781439
- Volume :
- 39
- Issue :
- 7
- Database :
- Academic Search Index
- Journal :
- Urologic Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 151384166
- Full Text :
- https://doi.org/10.1016/j.urolonc.2021.02.007